Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Efficacy of ICS versus Non-ICS Combination Therapy in COPD: A Meta-Analysis of Randomised Controlled Trials

Tytuł:
Efficacy of ICS versus Non-ICS Combination Therapy in COPD: A Meta-Analysis of Randomised Controlled Trials
Autorzy:
Ding Y
Sun L
Wang Y
Zhang J
Chen Y
Temat:
meta-analysis
chronic obstructive pulmonary disease
inhaled corticosteroid
dual therapy
triple therapy
exacerbation.
Diseases of the respiratory system
RC705-779
Źródło:
International Journal of COPD, Vol Volume 17, Pp 1051-1067 (2022)
Wydawca:
Dove Medical Press, 2022.
Rok publikacji:
2022
Kolekcja:
LCC:Diseases of the respiratory system
Typ dokumentu:
article
Opis pliku:
electronic resource
Język:
English
ISSN:
1178-2005
Relacje:
https://www.dovepress.com/efficacy-of-ics-versus-non-ics-combination-therapy-in-copd-a-meta-anal-peer-reviewed-fulltext-article-COPD; https://doaj.org/toc/1178-2005
Dostęp URL:
https://doaj.org/article/c15e62ac444d4758b8b973ac8fa2dc99  Link otwiera się w nowym oknie
Numer akcesji:
edsdoj.15e62ac444d4758b8b973ac8fa2dc99
Czasopismo naukowe
Yanling Ding *, Lina Sun *, Ying Wang, Jing Zhang, Yahong Chen Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jing Zhang; Yahong Chen, Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, People’s Republic of China, Tel +86 13-8104-57631, Email jing_amy@126.com; chenyahong@vip.sina.comBackground: Several large randomized clinical trials (RCTs) have assessed the efficacy and safety of inhaled corticosteroid (ICS) combination regimens versus non-ICS therapy in patients with chronic obstructive pulmonary disease (COPD) at increased risk of exacerbation risk with mixed results.Methods: We performed a systematic literature review and meta-analysis of RCTs comparing the effect of ICS-containing combination therapy and non-ICS regimen in patients with COPD.Results: A total of 54 RCTs (N = 57,333) reported treatment effects on various outcomes and were eligible for inclusion. Overall, the number of patients experiencing moderate/severe exacerbations was significantly lower for ICS-containing combination therapy versus non-ICS therapy (RR: 0.86 [95% CI: 0.80– 0.93]). The annual rate of exacerbations was also significantly reduced by 22% (0.78 [0.72– 0.86]) with ICS-containing versus non-ICS therapy. The annual rate of exacerbations requiring hospitalisation was reduced by 31% versus non-ICS therapy (0.69 [0.54– 0.88]); similar reduction was observed for exacerbations requiring oral steroids (0.69 [0.66– 0.73]). Overall, the effect on trough FEV1 was comparable between ICS-containing and non-ICS therapies (follow-up: 6– 52 weeks); however, a significant improvement in lung function (trough FEV1) was observed for ICS/LABA versus LABA (MD: +0.04 L [0.03− 0.05]) and ICS/LABA/LAMA versus LAMA (MD: +0.09 L [0.05− 0.13]) regimens. In addition, a significant improvement in QoL was observed with ICS-containing versus non-ICS therapy (MD in SGRQ score: − 0.90 [− 1.50, − 0.31]).Conclusion: This meta-analysis demonstrated that a wide range of patients with COPD could benefit from dual and triple ICS-containing therapy.Keywords: meta-analysis, chronic obstructive pulmonary disease, inhaled corticosteroid, dual therapy, triple therapy, exacerbation

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies